Lubiprostone as a Treatment for Constipation in Parkinson's Disease
Status:
Terminated
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
Delayed colonic transient time secondary to a multi-degenerative process is the most likely
cause of constipation in idiopathic PD. Since lubiprostone demonstrated its ability to
accelerate colonic transit time in healthy volunteers in addition to activating the chloride
channels in the intestinal cells, it has the potential to improve constipation in patients
with PD with no subsequent adverse events on the control of the neurological manifestation of
PD. So we hypothesize the following:
1. Lubiprostone will improve ratings on the Bristol stool form scale (BSFS) in patients
with PD induced constipation compared to baseline.(primary)
2. Lubiprostone will increase the number of spontaneous bowel movements (SBM) per week,
compared to baseline. (secondary)
3. Lubiprostone will improve health related quality of life in subjects with PD induced
constipation. ( secondary)